Thrombotic Thrombocytopenic Purpura (TTP) care technology platforms are the digital infrastructure underpinning one of hematology's most life-threatening emergencies — integrating ADAMTS13 activity surveillance with urgent plasma exchange scheduling coordination, caplacizumab therapy management, TTP registry coordination dashboards, relapse surveillance through remote ADAMTS13 inhibitor monitoring, lactate dehydrogenase and platelet count trend tracking, thrombotic microangiopathy endpoint monitoring, and the emergency escalation pathways that enable hematologists to detect TTP relapse before patients develop the catastrophic thrombotic organ failure that defines untreated TTP mortality. When a TTP care platform is unavailable or degraded, hematologists cannot access ADAMTS13 activity results and platelet count trend data that define relapse risk, plasma exchange scheduling fails, and the longitudinal surveillance infrastructure that distinguishes stable remission from imminent TTP relapse collapses. Thrombotic Thrombocytopenic Purpura is a life-threatening thrombotic microangiopathy — caused by severe acquired deficiency of ADAMTS13, the von Willebrand factor–cleaving metalloprotease, resulting from autoantibodies that deplete functional ADAMTS13 below 10% of normal activity — in which ultra-large von Willebrand factor multimer accumulation drives spontaneous platelet aggregation in the microvasculature, producing the classic pentad of thrombocytopenia, microangiopathic hemolytic anemia, neurological dysfunction, renal impairment, and fever that carries greater than 90% untreated mortality; today, emergency plasma exchange removing autoantibodies and restoring ADAMTS13 activity combined with caplacizumab blocking platelet aggregation and rituximab suppressing ADAMTS13 inhibitor production have transformed TTP from a uniformly fatal emergency to a survivable condition — but survival requires continuous ADAMTS13 surveillance, urgent plasma exchange scheduling infrastructure, and the digital monitoring platforms that detect relapse before the microangiopathy cascade becomes irreversible. The platforms that track ADAMTS13 activity results, plasma exchange scheduling, caplacizumab administration, platelet count trajectories, LDH trends, and TTP registry coordination must remain continuously available — because missed ADAMTS13 activity depletion detection and delayed plasma exchange coordination lead to TTP relapse mortality.
This guide covers what Thrombotic Thrombocytopenic Purpura care technology platforms need to monitor, why continuous availability matters across the full spectrum of thrombotic microangiopathy management and relapse surveillance, and how to build a monitoring strategy that protects ADAMTS13 surveillance, plasma exchange coordination, caplacizumab management, and the TTP registry and relapse detection workflows that TTP care requires.
Why Thrombotic Thrombocytopenic Purpura Care Tech Platforms Cannot Afford Downtime
TTP management is built on three pillars: eliminating ADAMTS13 inhibiting autoantibodies through plasma exchange and rituximab, blocking platelet microvascular aggregation with caplacizumab during the acute phase, and maintaining long-term remission through ADAMTS13 activity surveillance to detect subclinical inhibitor rise before clinical relapse occurs. The platforms that support TTP programs must remain continuously available — because TTP carries the most extreme consequence of any digital monitoring failure in hematology, where a patient in apparent remission whose ADAMTS13 activity falls below 10% without generating an alert, and who develops full TTP relapse with neurological involvement and renal failure during a period of platform unavailability, faces a mortality risk that exceeds 10–20% even with optimal emergency plasma exchange — and where the digital monitoring infrastructure is the difference between relapse caught during subclinical ADAMTS13 inhibitor rise versus relapse presenting as a neurological emergency requiring intensive care admission.
ADAMTS13 activity surveillance is the primary TTP relapse prevention tool. TTP relapse risk is defined by serial ADAMTS13 activity measurement — with ADAMTS13 activity recovery above 10% defining remission, activity remaining below 10% signaling persistent severe deficiency requiring continued treatment, and inhibitor titer trends providing the earliest biochemical signal of autoantibody-mediated ADAMTS13 depletion preceding clinical relapse by weeks to months. Digital monitoring platforms that aggregate serial ADAMTS13 activity and inhibitor titer results, generate threshold alerts when ADAMTS13 activity falls below patient-specific relapse risk thresholds, and integrate ADAMTS13 trajectories with clinical biomarker trends enable the preemptive rituximab retreatment that prevents clinical TTP relapse. ADAMTS13 activity monitoring is life-safety infrastructure in TTP — activity surveillance platform failures create relapse detection blind spots that allow TTP to develop to full clinical severity before intervention.
Plasma exchange scheduling is an acute emergency coordination function. TTP plasma exchange must be initiated within hours of diagnosis or relapse suspicion — with delays in plasma exchange initiation associated with directly increased mortality — and digital platforms that coordinate plasma exchange scheduling, notify apheresis teams of urgent TTP presentations, manage plasma product availability, and track daily plasma exchange response monitoring represent the emergency coordination infrastructure whose failure directly contributes to TTP relapse mortality.
Caplacizumab management requires real-time dosing and monitoring coordination. Caplacizumab — the anti-von Willebrand factor nanobody that blocks platelet microvascular aggregation in acute TTP — requires daily subcutaneous administration during plasma exchange and for 30 days after the last plasma exchange, with ongoing platelet count monitoring to guide treatment duration decisions and bleeding risk assessment. Digital platforms that track caplacizumab administration, monitor platelet count response, detect the platelet count rebound pattern that signals TTP reactivation after caplacizumab discontinuation, and coordinate the extended treatment duration decisions enable the optimal caplacizumab management that prevents rebound TTP after treatment withdrawal.
TTP registry coordination enables population-level relapse surveillance. TTP specialty programs rely on registry coordination platforms to maintain longitudinal patient records — integrating serial ADAMTS13 activity results, plasma exchange history, rituximab infusion cycles, caplacizumab treatment records, and relapse event documentation across patient populations in which each relapse represents a life-threatening emergency. Registry platform failures that break longitudinal ADAMTS13 surveillance records prevent the population-level relapse pattern identification that guides intensified monitoring after initial episodes.
Neurological and organ function monitoring defines acute TTP severity. Acute TTP with neurological involvement — confusion, seizures, stroke, coma — requires continuous neurological function monitoring and the digital platforms that capture neurological assessment scores, renal function trends, troponin elevation for cardiac microangiopathy, and serial platelet and LDH results define the severity trajectory that determines plasma exchange intensity and immunosuppression escalation.
What to Monitor on a Thrombotic Thrombocytopenic Purpura Care Tech Platform
ADAMTS13 Activity and Inhibitor Surveillance Dashboard
The ADAMTS13 activity and inhibitor titer monitoring service — integrating serial ADAMTS13 activity result feeds, inhibitor titer trend analysis, threshold alert generation for ADAMTS13 activity falling below patient-specific relapse risk thresholds, and integration with clinical biomarker trend data — is the highest-priority monitoring target. Check at a 1-minute interval with immediate escalation. ADAMTS13 activity surveillance is the primary mechanism for detecting subclinical TTP relapse before clinical microangiopathy recurs; dashboard failures that prevent real-time ADAMTS13 activity alert delivery create relapse detection blind spots in a condition where delayed intervention results in preventable death.
Plasma Exchange Scheduling and Apheresis Coordination Platform
Monitor the urgent plasma exchange scheduling service — including apheresis team notification, plasma product availability coordination, daily plasma exchange response monitoring, plasma volume calculation, and treatment response tracking — at a 1-minute interval. Plasma exchange initiation within hours of TTP diagnosis or relapse suspicion is life-saving; scheduling platform failures that delay apheresis team notification or plasma product coordination at the moment of urgent TTP presentation directly increase TTP relapse mortality.
Caplacizumab Administration and Response Monitoring Platform
Monitor the caplacizumab dose tracking, daily administration confirmation, platelet count response monitoring, treatment duration management, bleeding complication surveillance, and reactivation alert generation service at a 1-minute interval. Caplacizumab is the primary mechanism for immediately blocking platelet microvascular aggregation in acute TTP; administration tracking failures, missed reactivation alerts after treatment withdrawal, and bleeding complication surveillance failures represent safety-critical platform failures in the most dangerous acute phase of TTP management.
TTP Registry and Longitudinal Surveillance Platform
Monitor the TTP patient registry service — integrating longitudinal ADAMTS13 activity records, plasma exchange treatment history, rituximab infusion cycle records, relapse event documentation, and population-level relapse pattern analysis — at a 1-minute interval. TTP registry integrity is the foundation of longitudinal relapse surveillance and rituximab retreatment decision-making; registry platform failures that break ADAMTS13 surveillance continuity prevent the preemptive retreatment that prevents clinical TTP relapse.
Acute TTP Clinical Monitoring Dashboard
Monitor the neurological function assessment service — including confusion and cognitive function tracking, seizure event logging, renal function trend monitoring, troponin and cardiac biomarker feeds, serial platelet count and LDH result integration, and microangiopathic hemolysis activity quantification — at a 1-minute interval. Acute TTP with neurological, renal, and cardiac microangiopathy involvement requires continuous clinical severity monitoring; dashboard failures that interrupt neurological assessment documentation or fail to deliver critical biomarker alerts delay plasma exchange intensification in the most dangerous presentations.
Rituximab Therapy Coordination and B-Cell Monitoring
Monitor the rituximab infusion scheduling, B-cell count monitoring, CD20+ lymphocyte result feeds, pre-infusion safety checklist, and retreatment alert generation for rising ADAMTS13 inhibitor titers at a 2-minute interval. Rituximab is the primary mechanism for sustained ADAMTS13 inhibitor suppression in autoimmune TTP; scheduling failures or missed retreatment alerts when inhibitor titers rise allow autoantibody recovery and TTP relapse in patients who had achieved remission.
Patient-Reported Symptom Monitoring
Monitor the symptom diary submission platform — including neurological symptom reporting (headache, confusion, visual changes), fatigue tracking, bleeding event logging, and emergency symptom escalation pathway — at a 2-minute interval. Patient-reported neurological symptoms in TTP remission patients represent potential relapse signals; platform failures that prevent neurological symptom submission delay the urgent evaluation that distinguishes TTP relapse from intercurrent neurological illness.
Telemedicine and Hematology Coordinator Platform
Monitor the telemedicine session API, hematology nurse coordinator messaging, and remote consultation infrastructure at a 2-minute interval. TTP relapse surveillance depends on telemedicine for between-visit ADAMTS13 result review, caplacizumab continuation counseling, rituximab retreatment decision support, and early relapse symptom triage — access failures delay the clinical decisions that determine whether a rising ADAMTS13 inhibitor receives preemptive rituximab or progresses to clinical TTP.
EHR Integration Endpoint
Monitor the EHR synchronization service at a 5-minute interval. TTP patients presenting with acute relapse require immediate emergency department access to their ADAMTS13 activity history, plasma exchange treatment history, current caplacizumab status, and rituximab infusion records to enable rapid TTP recognition and emergency plasma exchange initiation.
Authentication Service
Monitor authentication at a 1-minute interval. Auth failures lock hematologists and TTP care coordinators out of ADAMTS13 surveillance dashboards, plasma exchange scheduling platforms, and caplacizumab management systems simultaneously.
SSL Certificates Across All Platform Domains
Monitor certificate expiry 30 days in advance across all patient-facing, clinician-facing, and integration domains.
Alerting Strategy for Thrombotic Thrombocytopenic Purpura Care Tech Platforms
Immediate clinical escalation (24/7): ADAMTS13 activity and inhibitor surveillance dashboard, plasma exchange scheduling and apheresis coordination platform, caplacizumab administration and response monitoring, acute TTP clinical monitoring dashboard, authentication service. These affect real-time TTP relapse detection and life-safety emergency coordination continuously.
Immediate clinical operations escalation: TTP registry and longitudinal surveillance platform, patient-reported symptom monitoring. Failures here directly affect relapse pattern surveillance and early neurological symptom triage.
High-priority immediate escalation: Rituximab therapy coordination and B-cell monitoring, telemedicine and hematology coordinator platform. Access failures interrupt inhibitor suppression management and the remote clinical support that TTP remission patients depend on.
Business-hours engineering escalation: EHR synchronization. Investigate within one business hour.
Advance warning: SSL certificate expiry, 30 days in advance, across all patient-facing and integration domains.
ADAMTS13 activity surveillance and plasma exchange scheduling require 24/7 alerting because TTP is a relapsing-remitting autoimmune thrombotic microangiopathy with greater than 10% relapse mortality — nighttime platform failures that prevent automated ADAMTS13 activity threshold alerts or block apheresis team emergency notifications create relapse detection blind spots in a condition where the interval between early ADAMTS13 inhibitor rise and clinical TTP relapse with life-threatening neurological, renal, and cardiac microangiopathy can be measured in hours to days, and where delayed plasma exchange initiation directly increases relapse mortality.
Status Page as a Clinical Safety Signal
Hematology nurses coordinating after-hours contacts from TTP remission patients reporting new headache, confusion, visual changes, unusual fatigue, or neurological symptoms need immediate platform status awareness before initiating emergency escalation protocols. A published status page allows on-call coordinators to distinguish a platform incident from patient connectivity problems — and to initiate phone-based triage and emergency department routing immediately when the digital platform is confirmed unavailable.
For TTP programs coordinating ADAMTS13 surveillance, plasma exchange scheduling, and caplacizumab management across geographically dispersed patient populations — many of whom live with the knowledge that each platelet count and ADAMTS13 result is a life-or-death monitoring point — a status page enables rapid identification of platform failures and activation of manual telephone-based relapse surveillance protocols. Publish the status page URL in care coordinator workstations, on-call hematology systems, apheresis unit scheduling dashboards, and emergency department TTP protocol documents.
The Business Case: Relapse Prevention, Mortality Reduction, and TTP Program Quality
TTP specialty programs face the highest cost and mortality exposure of any autoimmune hematological disorder — with TTP relapse hospitalizations carrying ICU admission rates above 50%, plasma exchange course costs measured in tens of thousands of dollars per episode, neurological sequelae from delayed treatment requiring long-term rehabilitation, and the irreplaceable human cost of preventable TTP relapse deaths in young patients who had achieved remission through plasma exchange and rituximab. Relapse prevention through continuous ADAMTS13 activity surveillance, preemptive rituximab retreatment before clinical microangiopathy recurs, and rapid plasma exchange scheduling represents the highest-value intervention in TTP care. Platform reliability that supports continuous ADAMTS13 monitoring is upstream of the most expensive and deadly outcomes in autoimmune thrombotic microangiopathy management.
Missed ADAMTS13 activity decline detection that delays rituximab retreatment represents preventable TTP relapse. Platforms that accurately capture serial ADAMTS13 activity and inhibitor titer trajectories and integrate them with platelet count trends, LDH data, caplacizumab administration records, and patient-reported neurological symptoms enable hematologists to distinguish subclinical inhibitor rise from stable remission before patients develop clinical TTP relapse.
TTP program quality metrics increasingly include relapse mortality rates, time-to-plasma-exchange-initiation after relapse diagnosis, ADAMTS13 activity monitoring compliance rates, and rituximab retreatment timeliness after inhibitor rise. Platform reliability is a direct input to outcome quality — programs whose monitoring platforms frequently fail will show higher TTP relapse mortality, delayed plasma exchange initiation, and preventable deaths in patients who needed continuous ADAMTS13 surveillance and urgent plasma exchange coordination.
External monitoring from Vigilmon provides the documented, independent availability record that TTP program directors can present to hospital administration, payer medical directors, and rare disease registries as evidence that the program's digital infrastructure supports the level of continuous ADAMTS13 surveillance that life-threatening autoimmune thrombotic microangiopathy management requires.
Vigilmon Setup for Thrombotic Thrombocytopenic Purpura Care Tech Platforms
A practical starting configuration:
| Monitor | Check Interval | Alert Channel | |---------|----------------|---------------| | ADAMTS13 activity and inhibitor surveillance dashboard | 1 min | PagerDuty (immediate, 24/7) | | Plasma exchange scheduling and apheresis coordination | 1 min | PagerDuty (immediate, 24/7) | | Caplacizumab administration and response monitoring | 1 min | PagerDuty (immediate, 24/7) | | Acute TTP clinical monitoring dashboard | 1 min | PagerDuty (immediate, 24/7) | | Auth service | 1 min | PagerDuty (immediate) | | TTP registry and longitudinal surveillance platform | 1 min | PagerDuty + Slack (immediate) | | Rituximab therapy coordination and B-cell monitoring | 2 min | PagerDuty (immediate) | | Patient-reported symptom monitoring | 2 min | PagerDuty (immediate) | | Telemedicine and hematology coordinator platform | 2 min | PagerDuty (immediate) | | EHR synchronization endpoint | 5 min | Slack (business hours) | | SSL: all platform domains | Daily | Email (30-day warning) |
Getting started:
- Create a free account at vigilmon.online
- Add the ADAMTS13 activity and inhibitor surveillance dashboard at a 1-minute interval with 24/7 PagerDuty alerting
- Add the plasma exchange scheduling and apheresis coordination platform and caplacizumab monitoring at a 1-minute interval with immediate 24/7 escalation
- Add the acute TTP clinical monitoring dashboard and TTP registry platform with immediate alerting
- Add rituximab therapy coordination and patient-reported symptom monitoring with immediate alerting
- Add telemedicine and hematology coordinator platform monitoring
- Add authentication and EHR synchronization
- Enable SSL monitoring across all patient-facing and integration domains
- Publish the automatic status page URL in care coordinator workstations, on-call hematology systems, apheresis unit dashboards, and emergency department TTP protocol systems
Conclusion
Thrombotic Thrombocytopenic Purpura care tech platforms hold the ADAMTS13 surveillance and plasma exchange coordination infrastructure that makes one of hematology's deadliest conditions survivable — ADAMTS13 activity monitoring systems, inhibitor titer surveillance dashboards, plasma exchange scheduling platforms, caplacizumab administration management tools, TTP registry coordination services, acute clinical monitoring dashboards, and telemedicine access points that cannot undo the TTP relapses, neurological injuries, and preventable deaths accumulated during periods of unmonitored ADAMTS13 activity decline. Their availability is a prerequisite for relapse prevention, plasma exchange emergency coordination, and the specialist surveillance that TTP remission patients depend on throughout a relapsing-remitting autoimmune condition that requires continuous ADAMTS13 activity monitoring, serial inhibitor titer surveillance, rituximab retreatment scheduling, caplacizumab management, and plasma exchange emergency coordination to maintain remission, prevent microangiopathic relapse, and detect the ADAMTS13 activity depletion — below 10% of normal — that defines TTP relapse risk before life-threatening thrombotic microangiopathy with neurological, renal, and cardiac involvement recurs. When ADAMTS13 surveillance dashboards go offline, plasma exchange scheduling platforms fail, or caplacizumab monitoring systems are unavailable, the clinical consequences extend to a disease where the difference between adequate and inadequate monitoring is measured in TTP relapse hospitalizations, ICU admissions, permanent neurological sequelae, and preventable deaths in patients whose ADAMTS13 inhibitor-mediated relapse needed to be detected at the subclinical stage, not in the emergency department with new neurological deficits.
External monitoring from Vigilmon provides the independent, outside-in availability view that TTP program directors and health system IT teams need to catch failures before they affect ADAMTS13 activity surveillance or plasma exchange emergency coordination — with the documented incident record that accreditation bodies, rare disease registries, and payer audit teams accept as evidence of operational maturity.
Start monitoring your Thrombotic Thrombocytopenic Purpura care tech platform for free at vigilmon.online — HTTP/HTTPS monitoring, multi-region consensus alerting, SSL certificate monitoring, automatic status page, Slack and PagerDuty integration. No agent required. No credit card.
Tags: #monitoring #TTP #ThromboticThrombocytopenicPurpura #ADAMTS13 #plasmaexchange #caplacizumab #rituximab #thrombosis #microangiopathy #hematology #raredisease #autoimmune #healthtech #uptime #clinicaldocumentation #sre